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Abstract  33 
Background 34 
IgA antibodies targeting Epstein-Barr virus (EBV) have been proposed for screening for nasopharyngeal 35 
carcinoma (NPC).  However, methods vary, and antigens used in these assays differ considerably between 36 
laboratories.   37 
Methods 38 
To enable formal comparisons across a range of established EBV serology assays, we created a panel of 39 
66 pooled serum and 66 pooled plasma samples generated from individuals with a broad range of IgA 40 
antibody levels.  Aliquots from these panels were distributed to six laboratories and tested by 26 assays 41 
measuring antibodies against VCA, EBNA1, EA-EBNA1, Zta, or EAd antigens.  We estimated the 42 
correlation between assay-pairs using Spearman coefficients (continuous measures) and percentage 43 
agreement (positive versus negative using pre-defined positivity cutoffs by each assay 44 
developer/manufacturer).   45 
Results 46 
While strong correlations were observed between some assays, considerable differences were also noted, 47 
even for assays that targeted the same protein.  For VCA-IgA assays in serum, two distinct clusters were 48 
identified, with the median Spearman coefficient of 0.41 (range: 0.20 – 0.66) across these two clusters.  49 
EBNA1-IgA assays in serum grouped into a single cluster with the median Spearman coefficient of 0.79 50 
(range: 0.71 – 0.89).  Percentage agreements varied broadly for both VCA-IgA (12% – 98%) and 51 
EBNA1-IgA (29% – 95%) assays in serum.  Moderate-to-strong correlations were observed across assays 52 
in serum that targeted other proteins (correlations range: 0.44 – 0.76).  Similar results were noted for 53 
plasma.  54 
Conclusion 55 
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Standardization of EBV serology assays is needed to allow for comparability of results obtained in 56 
different translational research studies across laboratories and populations.  57 
 58 
  59 
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Introduction 60 
Assays that measure antibody responses to Epstein-Barr virus (EBV) have become increasingly 61 
important tools for studying and diagnosing nasopharyngeal carcinoma (NPC) and other research (1, 2).  62 
Several studies have shown that individuals with elevated levels of antibody responses against EBV 63 
antigens (particularly IgA responses) are at increased risk for the development of NPC (3-15).  In NPC 64 
endemic areas such as Southern China, EBV IgA antibody testing has been proposed for general 65 
population screening to triage individuals to further clinical evaluation aiming at the early detection and 66 
treatment of NPC (4, 7, 16, 17).  However, recent studies have elucidated the underlying (epitope) 67 
complexity of anti-EBV antibody responses, and this needs to be considered in order to achieve 68 
standardization amongst the community (2). 69 
IgA antibodies against EBV capsid antigen (VCA-IgA) and EBV nuclear antigen 1 (EBNA1-IgA) 70 
are the two EBV serological markers most frequently considered for screening purposes (4, 7, 16-18).  71 
However, several assays that measure VCA-IgA and EBNA1-IgA exist, and efforts to standardize these 72 
EBV assays have been limited, making it difficult to compare results across studies that utilize different 73 
assays.  To date, no studies have directly compared VCA- or EBNA1-IgA results from the various assays 74 
used in different laboratories globally to define interassay agreement or to assess whether the same 75 
humoral immune response is being measured by each assay.  As such markers have been proposed for use 76 
in NPC early-detection screening programs. Understanding the relationship between existing commercial 77 
and research assays is needed to interpret the published literature.  Evaluation of the correlation and 78 
percentage agreement between assays represents an important initial step toward the standardization for 79 
assays intended for clinical use. 80 
 To measure agreement between assays measuring antibodies against EBV, we conducted a study 81 
in which pools of serum and plasma from individuals with a range of expected antibody levels were 82 
created and blindly distributed to six different laboratories for testing. We initially focused on assays that 83 
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measure antibodies against VCA and EBNA1 because those are the two main EBV antigens targeted for 84 
antibody tests considered for EBV screening purposes. Herein, we described the various laboratories’ 85 
methods and correlation/agreement between assays.  For completeness, we also included assays that 86 
measure antibodies against other EBV proteins (e.g., early D antigen [EAd] and Zta) to understand the 87 
correlations between assays that measure antibodies against these different proteins.  88 
Methods 89 
Source population 90 
 This panel of EBV serology standards was created by capitalizing on biospecimen resources from 91 
ongoing and completed studies conducted in Taiwan (10, 19) between 1991 and 2016.  Serum and plasma 92 
samples were prepared within 24 hr of collection and stored frozen at -80°C until analysis.  These studies 93 
were reviewed/approved by the National Cancer Institute Special Studies Institutional Review Board and 94 
the National Taiwan University Institutional Review Board.  Written informed consent was obtained for 95 
all participants. 96 
Creating pools for testing 97 
To create a resource with sufficient volume to permit testing by multiple assays in multiple 98 
laboratories, pooling samples across individuals was required.  We created both serum and plasma pools 99 
with different individuals contributing samples for serum pools and plasma pools because of limited 100 
specimen availability from the previous studies.  To ensure that a broad distribution of IgA antibody 101 
responses was retained after pooling, blood samples from individuals with similar expected IgA responses 102 
were pooled whenever possible.  IgA antibody titers at collection were retrieved from participants’ 103 
medical files or experimental records at collection, based on different IgA assays in routine clinical use at 104 
the time each of the studies was conducted. Briefly, a total of 66 pooled serum samples and 66 pooled 105 
plasma samples were generated from an average of two individuals (range: 1-5), of which 22 pooled 106 
serum/plasma samples were created from 1) NPC cases (representing samples with potentially elevated 107 
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IgA antibody titers) and non-NPC cases with known high levels of IgA antibodies against EBV, 2) 108 
general population controls from a previously conducted NPC case-control study (representing samples 109 
expected to have low IgA antibody titers) and hospital outpatients with known low levels of IgA 110 
antibodies against EBV, and 3) unaffected individuals from an ongoing NPC multiplex family study 111 
(representing individuals at high risk of developing NPC).   112 
Plate batching of pools 113 
 Participating laboratories were provided with one aliquot (range: 25µl – 150µl) of each sample 114 
without knowledge of whether the sample came from high-risk or low-risk pools.  We also included 115 
approximately 20% randomly selected, blinded duplicate samples (N=14) to assess within-assay 116 
intraclass correlation coefficients (ICCs) and coefficients of variation (CV).  All samples were randomly 117 
distributed on the plate and sent to participating laboratories in individual cryovials.   118 
Assays performed 119 
 Six independent laboratories agreed to test serum and/or plasma specimens using research or 120 
commercial assays (enzyme-linked immunosorbent assay [ELISA] or Luminex assays).  Of the 26 assays, 121 
two VCA-IgA assays (A2.1 and A2.2) and two EBNA1-IgA assays (A9.1 and A9.2) comprised 122 
commercial assays purchased from the same company but tested in different laboratories with different 123 
pre-defined positivity cutoffs.  No special instructions were given to the laboratories regarding the 124 
handling or testing of these specimens.  Details of each assay, including information on sample dilution, 125 
antigens targeted, amino acid sequences, and whether the assays were designed to capture IgA, IgG, or 126 
IgG/IgA/IgM are provided in Supplementary Materials and Supplementary Table 1.  In total, we 127 
included eight assays designed to measure antibodies against VCA, of which six assays were designed to 128 
detect IgA, one assay was designed to detect IgG/IgA/IgM, and one assay was designed to detect IgG. 129 
Nine assays designed to measure antibodies against EBNA1, of which six assays were designed to detect 130 
IgA, two assays were designed to detect IgG/IgA/IgM, and one assay was designed to detect IgG. Nine 131 
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assays were designed to measure antibodies against other antigens (i.e., EA-EBNA1, Zta and EAd), of 132 
which two assays were designed to detect IgA against EA-EBNA1 combined, four assays were designed 133 
to detect antibodies against EAd (two for IgA, one for IgG/IgA/IgM and one for IgG), and three assays 134 
were designed to detect antibodies against Zta (two for IgA and one for IgG/IgA/IgM).  135 
Statistical Analysis 136 
 We first utilized the blinded duplicate pools included in our panel to estimate reproducibility of 137 
the 26 assays performed as part of our effort.  For each specimen type (i.e., serum or plasma), assays were 138 
clustered according to their Spearman correlations using unsupervised hierarchical clustering with 139 
Euclidean distance and complete linkage (20).  Correlation coefficients of larger than 0.7, between 0.5 140 
and 0.7, and less than 0.5 were considered to be strong, modest, and weak correlations, respectively (21).  141 
We also estimated percentage agreement and Kappa value between assay pairs using pre-defined 142 
positivity cutoffs for IgA assays as these IgA assays have been proposed for screening for NPC 143 
(Supplementary Table 1).  144 
Analyses were performed using R Statistical Software (Foundation for Statistical Computing, 145 
Vienna, Austria).  All statistical tests were 2-sided, and P < 0.05 was considered statistically significant. 146 
Results 147 
 After quality control, we excluded from further consideration six assays evaluating serum (i.e., 148 
Assays A18, A19, A21, A22, A23, and A24) and five evaluating plasma (i.e., Assays A3, A9.2, A14, 149 
A23, and A24) with ICC<0.8 or CV>20% (Table 1).  Among assays measuring antibodies against VCA, 150 
we included eight assays (six IgA, one IgG, and one IgG/IgA/IgM) for serum and seven assays (five IgA, 151 
one IgG, and one IgG/IgA/IgM) for plasma.  Among assays measuring antibodies against EBNA1, we 152 
included nine assays (six IgA, one IgG, and two IgG/IgA/IgM) for serum and seven assays (five IgA, one 153 
IgG, and one IgG/IgA/IgM) for plasma.  Among assays measuring antibodies against other antigens (i.e., 154 
EAd and Zta), we included two assays (all IgA) for serum and six assays (three IgA, one IgG, and two 155 
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IgG/IgA/IgM) for plasma in the analysis.  The average response levels are summarized in Table 1 and 156 
results stratified by our three pre-defined groups are shown in Supplementary Table 2.   157 
Antibodies against VCA 158 
 The correlations between assays measuring antibodies against VCA in serum are presented in 159 
Figure 1A.  A total of three clusters were identified.  Correlations tended to be higher within rather than 160 
across immunoglobin classes (Clusters #1 and #2 vs. Cluster #3; Cluster #3 representing IgG and 161 
IgG/IgA/IgM).  IgA only assays grouped into two clusters: Cluster #1 included three research assays 162 
measuring the same antigen (VCA-p18; [Assays A1, A4, and A5] sequences illustrated in 163 
Supplementary Figure 1) with a median Spearman coefficient of 0.85 (range: 0.85 – 0.87); Cluster #2 164 
included two commercial assays (assays A2.1/A2.2 and A3.  Assays A2.1 and A2.2 were purchased from 165 
the same company but tested by two different labs) with a median Spearman coefficient of 0.71 (range: 166 
0.64 – 0.97).  Weak-to-moderate correlations were observed among IgA assays across Clusters #1 and #2, 167 
with a median Spearman coefficient of 0.41 (range: 0.20 – 0.66). The lowest correlation was observed 168 
between assays A2.2 and A5 (Spearman coefficient = 0.20).   169 
 Among IgA only assays, the percentage agreement for serum varied considerably from 12% - 98% 170 
(Kappa values ranged from -0.03 to 0.9, Table 2).  Higher agreements were observed between assays that 171 
clustered together in Figure 1 (e.g., between assays A2.1 and A2.2, 95%; and between assays A4 and A5, 172 
98%).  By contrast, lower agreements were observed between assays that clustered separately (Figure 1, 173 
e.g., between assays A1 and A3, 12%; and between assays A3 and A5, 15%).  174 
Antibodies against EBNA1 175 
The correlations between assays measuring antibodies against EBNA1 in serum are presented in 176 
Figure 1B.  Again, among three clusters that were identified, correlations tended to be higher within 177 
rather than across immunoglobin classes (Cluster #1 vs Clusters #2 and #3; Clusters #2 and #3 178 
representing IgG/IgA/IgM and IgG).  In contrast to observations made for VCA, all IgA only assays 179 
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10 
grouped into a single cluster (sequences illustrated in Supplementary Figure 2), with a median 180 
Spearman coefficient of 0.79 (range: 0.71 – 0.89).  However, a wide range of percentage agreement (29% 181 
– 95%, Kappa values ranged from 0.1 to 0.9, Table 3) was observed for these IgA assays.  182 
Antibodies against other EBV antigens (i.e., Zta and EAd) 183 
 To understand the correlations between assays measuring antibodies against distinct EBV 184 
proteins (i.e., Zta, EAd, VCA and EBNA1,) we compared results from assays targeting Zta and EAd 185 
(sequences illustrated in Supplementary Figure 3) against representative assays targeting VCA and 186 
EBNA1.  Specifically, for this evaluation we included one IgA assay for each of the two clusters 187 
identified for VCA IgA (assays A1 and A2.1) and one assay from the single cluster identified for EBNA1 188 
IgA (assay A8).  The correlations between those assays in serum are shown in Figure 1C.  Weak-to-189 
moderate correlations were observed for IgA assays, with a median Spearman coefficient of 0.60 (range: 190 
0.44 – 0.76).   191 
Results in plasma 192 
Similar correlations were observed in serum as in plasma when comparisons were made across 193 
assays and results are presented in Supplementary Figure 4 and Supplementary Tables 3-4. 194 
Discussion 195 
IgA antibodies against EBV VCA and EBNA1 have been proposed to facilitate diagnosis and 196 
early detection of NPC in high incidence regions (9, 17, 18).  However, there has been very little effort to 197 
standardize the assays being considered for such programs and to understand the similarities and 198 
differences in their performance.  Herein, we report the first study to directly compare assays designed to 199 
measure these antibodies.  Although we observed high correlation and agreement between some assays, 200 
our results demonstrate wide variability among the assays evaluated when assays were compared with 201 
respect to both antibody levels and serostatus.  Such variability could be caused by differences in targeted 202 
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11 
antigens, detection methods, and dynamic range of assays.  These findings highlight the need for more 203 
formal attempts to validate and standardize EBV serology assays that are being considered or used for 204 
population screening or clinical diagnosis aimed at the early detection of NPC. 205 
In the present study, clear differences were observed for assays designed to detect antibodies 206 
against VCA.  Although a low agreement between assays designed to measure different Ig classes (IgG 207 
vs. IgA) was expected (22), two distinct clusters of IgA assays were noted.  For these two clusters, good 208 
agreement was noted for assays contained within a cluster while poor agreement was observed for assays 209 
contained across clusters.  The high correlation within clusters is likely explained by sharing of 210 
antigens/epitopes targeted by these assays (e.g., assays A1, A4, and A5 targeted VCA-p18, one of six 211 
proteins comprising the EBV viral capsid), although in some instances (assays A2.1, A2.2, and A3) we 212 
could not confirm this fact since information on target probes was not disclosed by the assay 213 
developer/manufacturer.  The EBV VCA is a complex containing major capsid protein (p160; BcLF1), 214 
small capsid protein (VCA-p18, BFRF3), scaffold protein (VCA-p40, BdRF1), tegument protein p23 215 
(BLRF2), glycoproteins gp125/110 (BALF4), and gp350/220 (BLLF1) (2).  The immunodominant and 216 
virus-specific antigenic domain of VCA-p18 has been mapped and is located in its C-terminus (AA 110-217 
176), whereas such domain is less clear for other VCA complex proteins (2).  It is expected that different 218 
VCA components will contain distinct immunodominant domains, induce different levels of antibody 219 
response, and have different diagnostic performance.  Moving forward, reporting of probe sequences used 220 
to measure EBV VCA antibodies will be important to facilitate interpretation of results across studies.     221 
For EBNA1, we noted poor agreement for assays designed to detect different Ig classes but better 222 
agreement for assays designed to detect IgA, suggesting that these assays target similar epitopes.  In fact, 223 
review of the probe sequences used to capture antibodies against EBNA1 revealed overlap across all 224 
assays for AA 382-404.  This is consistent with reports that an immunodominant epitope of the EBNA1 225 
protein (BKRF1, the major antigenic component of the EBNA complex), is located within AA 390-450 226 
(2, 13, 23).  Nonetheless, it is important to note that despite the high correlation observed for EBNA1 IgA 227 
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12 
assays, the range of percentage positive agreements between these assays was wide, suggesting varying 228 
sensitivities or thresholds for defining a positive response.  The seropositivity cut-point we applied for 229 
each assay was predefined by the assay developers/manufacturers.  These different assay positivity rates 230 
further highlight the need for careful validation and standardization of these assays in the future. 231 
The moderate correlations for assays measuring IgA antibodies against different EBV proteins 232 
(VCA, EBNA1, EAd and Zta) was included in this report for completeness and provides a useful 233 
benchmark when evaluating levels of agreement for VCA and EBNA1 assays.  Rates of agreement across 234 
protein targets were consistent with previous findings (22).  The elevated levels of anti-EBV antibodies 235 
could indicate the ongoing viral lytic activity (reactivation) and a potential lack of control over the virus 236 
in general.  Noteworthy is the fact that levels of agreement observed across proteins (expected to be 237 
modest) overlap with those noted within proteins (expected to be high for well standardized and 238 
characterized assays), again highlighting the need for further assay standardization in the future. 239 
Strengths of our study included carefully selected pools meant to represent the entire expected 240 
range in antibody levels, direct comparison of assays using these pools, inclusion of many assays and 241 
laboratories.  However, our results should be interpreted in light of some limitations.  First, serum and 242 
plasma samples were not collected from the same individuals, which precludes us from formally 243 
comparing the antibody level and its correlation between serum and plasma based on paired samples. 244 
Second, information on the nature of EBV antigen used was missing for a few assays, which precludes us 245 
from further exploring the factors causing variability across different assays. 246 
 In conclusion, using a carefully-defined panel of serum and plasma samples distributed among 247 
multiple reference laboratories, we report high agreement for some assays designed to measure antibodies 248 
against same EBV antigens.  However, we also observed considerable variability in the agreement 249 
between assays designed to measure antibodies against EBV VCA and EBNA1, both with respect to their 250 
correlation and to their reported positivity rates.  Our study highlights the need for more systematic 251 
standardization of these assays and for the development of an international standard for measuring these 252 
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13 
antibody responses in serum or plasma.  Such efforts are pre-requisites for the formal evaluation and 253 
quantitation of the performance of these assays in clinical practice or for population-based screening 254 
aimed at the early detection of NPC in high incidence regions. 255 
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Figure Legends 260 
Figure 1. Unsupervised hierarchical clustering based on Spearman correlation coefficient between assays 261 
measuring anti-EBV antibodies in serum.  A) Antibodies against EBV capsid antigen (VCA); B) 262 
Antibodies against EBV nuclear antigen 1 (EBNA1); C) Antibodies against Zta (ZEBRA), early D 263 
antigen (EAd), VCA, and EBNA1. Red depicts a strong positive correlation, and blue indicates a weak 264 
correlation. 265 
Reference 266 
1. Coghill AE, Hildesheim A. 2014. Epstein-Barr virus antibodies and the risk of associated 267 
malignancies: review of the literature. Am J Epidemiol 180:687-95. 268 
2. Middeldorp JM. 2015. Epstein-Barr Virus-Specific Humoral Immune Responses in Health and 269 
Disease. Curr Top Microbiol Immunol 391:289-323. 270 
3. Zeng Y, Zhang LG, Li HY, Jan MG, Zhang Q, Wu YC, Wang YS, Su GR. 1982. Serological mass 271 
survey for early detection of nasopharyngeal carcinoma in Wuzhou City, China. Int J Cancer 272 
29:139-41. 273 
4. Zeng Y, Zhong JM, Li LY, Wang PZ, Tang H, Ma YR, Zhu JS, Pan WJ, Liu YX, Wei ZN, et al. 1983. 274 
Follow-up studies on Epstein-Barr virus IgA/VCA antibody-positive persons in Zangwu County, 275 
China. Intervirology 20:190-4. 276 
5. Zong YS, Sham JS, Ng MH, Ou XT, Guo YQ, Zheng SA, Liang JS, Qiu H. 1992. Immunoglobulin A 277 
against viral capsid antigen of Epstein-Barr virus and indirect mirror examination of the 278 
nasopharynx in the detection of asymptomatic nasopharyngeal carcinoma. Cancer 69:3-7. 279 
6. Chien YC, Chen JY, Liu MY, Yang HI, Hsu MM, Chen CJ, Yang CS. 2001. Serologic markers of 280 
Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med 281 
345:1877-82. 282 
 o
n
 April 14, 2020 at JAM
ES CO
O
K UNIVERSITY
http://jcm.asm.org/
D
ow
nloaded from
 
14 
7. Ji MF, Wang DK, Yu YL, Guo YQ, Liang JS, Cheng WM, Zong YS, Chan KH, Ng SP, Wei WI, Chua DT, 283 
Sham JS, Ng MH. 2007. Sustained elevation of Epstein-Barr virus antibody levels preceding 284 
clinical onset of nasopharyngeal carcinoma. Br J Cancer 96:623-30. 285 
8. Hsu WL, Chen JY, Chien YC, Liu MY, You SL, Hsu MM, Yang CS, Chen CJ. 2009. Independent effect 286 
of EBV and cigarette smoking on nasopharyngeal carcinoma: a 20-year follow-up study on 9,622 287 
males without family history in Taiwan. Cancer Epidemiol Biomarkers Prev 18:1218-26. 288 
9. Liu Y, Huang Q, Liu W, Liu Q, Jia W, Chang E, Chen F, Liu Z, Guo X, Mo H, Chen J, Rao D, Ye W, 289 
Cao S, Hong M. 2012. Establishment of VCA and EBNA1 IgA-based combination by enzyme-290 
linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a 291 
two-stage design with a preliminary performance study and a mass screening in southern China. 292 
Int J Cancer 131:406-16. 293 
10. Yu KJ, Hsu WL, Pfeiffer RM, Chiang CJ, Wang CP, Lou PJ, Cheng YJ, Gravitt P, Diehl SR, Goldstein 294 
AM, Chen CJ, Hildesheim A. 2011. Prognostic utility of anti-EBV antibody testing for defining NPC 295 
risk among individuals from high-risk NPC families. Clin Cancer Res 17:1906-14. 296 
11. Coghill AE, Pfeiffer RM, Proietti C, Hsu WL, Chien YC, Lekieffre L, Krause L, Teng A, Pablo J, Yu KJ, 297 
Lou PJ, Wang CP, Liu Z, Chen CJ, Middeldorp JM, Mulvenna JP, Bethony J, Hildesheim A, Doolan 298 
DL. 2018. Identification of a novel, EBV-based antibody risk stratification signature for early 299 
detection of nasopharyngeal carcinoma in Taiwan. Clin Cancer Res doi:10.1158/1078-0432.CCR-300 
17-1929. 301 
12. Paramita DK, Fachiroh J, Haryana SM, Middeldorp JM. 2009. Two-step Epstein-Barr virus 302 
immunoglobulin A enzyme-linked immunosorbent assay system for serological screening and 303 
confirmation of nasopharyngeal carcinoma. Clin Vaccine Immunol 16:706-11. 304 
13. Fachiroh J, Paramita DK, Hariwiyanto B, Harijadi A, Dahlia HL, Indrasari SR, Kusumo H, Zeng YS, 305 
Schouten T, Mubarika S, Middeldorp JM. 2006. Single-assay combination of Epstein-Barr Virus 306 
(EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV 307 
immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma 308 
patients: options for field screening. J Clin Microbiol 44:1459-67. 309 
14. Fachiroh J, Prasetyanti PR, Paramita DK, Prasetyawati AT, Anggrahini DW, Haryana SM, 310 
Middeldorp JM. 2008. Dried-blood sampling for Epstein-Barr Virus immunoglobulin G (IgG) and 311 
IgA serology in nasopharyngeal carcinoma screening. J Clin Microbiol 46:1374-80. 312 
15. Hutajulu SH, Fachiroh J, Argy G, Indrasari SR, Indrawati LPL, Paramita DK, Jati TBR, Middeldorp 313 
JM. 2017. Seroprevalence of IgA anti Epstein-Barr virus is high among family members of 314 
nasopharyngeal cancer patients and individuals presenting with chronic complaints in head and 315 
neck area. PLoS One 12:e0180683. 316 
16. Zeng Y, Zhang LG, Wu YC, Huang YS, Huang NQ, Li JY, Wang YB, Jiang MK, Fang Z, Meng NN. 317 
1985. Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-318 
positive persons in Wuzhou City, China. Int J Cancer 36:545-7. 319 
17. Liu Z, Ji MF, Huang QH, Fang F, Liu Q, Jia WH, Guo X, Xie SH, Chen F, Liu Y, Mo HY, Liu WL, Yu YL, 320 
Cheng WM, Yang YY, Wu BH, Wei KR, Ling W, Lin X, Lin EH, Ye W, Hong MH, Zeng YX, Cao SM. 321 
2013. Two Epstein-Barr virus-related serologic antibody tests in nasopharyngeal carcinoma 322 
screening: results from the initial phase of a cluster randomized controlled trial in Southern 323 
China. Am J Epidemiol 177:242-50. 324 
18. Coghill AE, Hsu WL, Pfeiffer RM, Juwana H, Yu KJ, Lou PJ, Wang CP, Chen JY, Chen CJ, Middeldorp 325 
JM, Hildesheim A. 2014. Epstein-Barr virus serology as a potential screening marker for 326 
nasopharyngeal carcinoma among high-risk individuals from multiplex families in Taiwan. Cancer 327 
Epidemiol Biomarkers Prev 23:1213-9. 328 
 o
n
 April 14, 2020 at JAM
ES CO
O
K UNIVERSITY
http://jcm.asm.org/
D
ow
nloaded from
 
15 
19. Hildesheim A, Apple RJ, Chen CJ, Wang SS, Cheng YJ, Klitz W, Mack SJ, Chen IH, Hsu MM, Yang 329 
CS, Brinton LA, Levine PH, Erlich HA. 2002. Association of HLA class I and II alleles and extended 330 
haplotypes with nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst 94:1780-9. 331 
20. Galili T. 2015. dendextend: an R package for visualizing, adjusting, and comparing trees of 332 
hierarchical clustering. Bioinformatics.<doi:10.1093/bioinformatics/btv428>. 333 
21. Hinkle DE, Wiersma W, SG. J. Applied Statistics for the Behavioral Sciences. 5th ed. Boston: 334 
Houghton Mifflin; 2003. 335 
22. Liu Z, Coghill AE, Pfeiffer RM, Proietti C, Hsu WL, Chien YC, Lekieffre L, Krause L, Yu KJ, Lou PJ, 336 
Wang CP, Mulvenna J, Middeldorp JM, Bethony J, Chen CJ, Doolan DL, Hildesheim A. 2018. 337 
Patterns of Interindividual Variability in the Antibody Repertoire Targeting Proteins Across the 338 
Epstein-Barr Virus Proteome. J Infect Dis 217:1923-1931. 339 
23. Cameron B, Flamand L, Juwana H, Middeldorp J, Naing Z, Rawlinson W, Ablashi D, Lloyd A. 2010. 340 
Serological and virological investigation of the role of the herpesviruses EBV, CMV and HHV-6 in 341 
post-infective fatigue syndrome. J Med Virol 82:1684-8. 342 
343 
 o
n
 April 14, 2020 at JAM
ES CO
O
K UNIVERSITY
http://jcm.asm.org/
D
ow
nloaded from
 
16 
Table 1. Summary of titer for assays testing anti-EBV antibodies. 
Assay Antigen Antibody type Method Unit 
Serum   Plasma 
Median (IQR) 
a
 Min-Max   Median (IQR) 
a
 Min-Max 
VCA 
         
  A1 VCA-p18 IgA ELISA OD 4.28 (5.61) 1.25-22.58 
 
2.41 (3.63) 0.53-17.12 
  A2.1 VCA IgA ELISA relative OD 1.18 (2.92) 0.19-14.71 
 
0.7 (2.15) 0.15-13.5 
  A2.2 VCA IgA ELISA OD 0.92 (1.98) 0.19-10.8 
 
0.66 (2.06) 0.2-11 
  A3 b VCA IgA ELISA OD 0.07 (0.16) 0.01-0.9 
 
N/A N/A 
  A4 VCA-p18 IgA Luminex MFI 1737 (2726.75) 15-10615 
 
1105 (2517.25) 6-10231 
  A5 VCA-p18 IgA Luminex MFI 1682.5 (2932.5) 102-16524 
 
1082 (2317) 45-12190 
  A6 VCA-p18 IgG Luminex MFI 11466.25 (3455.62) 1256.5-21006 
 
13130.25 (6511.5) 1661-19609 
  A7 VCA-p18 IgG/IgA/IgM Luminex MFI 3065 (2764) 377-13253 
 
2444 (2073.5) 164-7492 
EBNA1 
       
  
  A8 EBNA1 IgA ELISA OD 1.12 (6.6) 0.7-25.5 
 
0.87 (4.04) 0.44-17.65 
  A9.1 EBNA1 IgA ELISA relative OD 0.44 (2.58) 0-5.07 
 
0.25 (2.01) 0.00-5.04 
  A9.2 b EBNA1 IgA ELISA OD 0.13 (1.09) 0-2.65 
 
N/A N/A 
  A10 EBNA1 IgA Luminex MFI 58 (1335.5) 5-1987 
 
38 (1353.75) 35796 
  A11 EBNA1 IgA Luminex MFI 277 (1434.75) 52-4994 
 
185.5 (1137.5) 19725 
  A12 EBNA1 IgA Luminex MFI 119 (966.88) 26-4131.5 
 
71.5 (658.25) 30-3403 
  A13 EBNA1 IgG Luminex MFI 10569.75 (4737.62) 345-16185 
 
10938 (7585.25) 290-17357.5 
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  A14 b  EBNA1 IgG/IgA/IgM Luminex MFI 3109 (2162) 89-17673 
 
N/A N/A 
  A15 EBNA1 IgG/IgA/IgM Luminex MFI 7741.5 (3384.75) 836-17545 
 
5816.5 (6303) 257-17412 
Other 
antigens 
       
  
  A16 EAd IgA Luminex MFI 147 (2003.75) 1-13243 
 
48.5 (2046.25) 1-13982 
  A17 EAd IgA Luminex MFI 96 (75.25) 37-2654 
 
62.75 (85.25) 29-14150 
  A18 b EAd  IgG Luminex MFI N/A N/A 
 
90.75 (610) 29-7846 
  A19 b EAd IgG/IgA/IgM Luminex MFI N/A N/A 
 
309.5 (1518) 1-15095 
  A20 Zta (ZEBRA) IgA Luminex MFI 30.5 (237) 1-5024 
 
18 (537.25) 1-8591 
  A21 b Zta (ZEBRA) IgA ELISA OD N/A N/A 
 
0.08 (0.11) 0.02-1.73 
  A22 b Zta (ZEBRA) IgG/IgA/IgM Luminex MFI N/A N/A 
 
268.5 (892) 1-6309 
  A23 b EA-EBNA1 IgA ELISA OD N/A N/A 
 
N/A N/A 
  A24 b EA-EBNA1 IgA ELISA OD N/A N/A 
 
N/A N/A 
Abbreviations: EBV (Epstein-Barr virus); EAd: early D antigen; EBNA1: EBV nuclear antigen 1; ELISA, enzyme-linked immunosorbent assay; MFI, median 
fluorescence intensity; OD, optical density; VCA: EBV capsid antigen.  
a. Median level is based on 66 pooled samples. 
b. Results are presented as “N/A” for assays with intraclass correlation coefficient (ICC) <0.8 or coefficients of variation (CV) >20%.   
 344 
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Table 2. Percentage agreement (Kappa) for assays detecting IgA antibodies against VCA in 
serum. 
a
 
Assay A1 A2.1 A2.2 A3 A4 A5 
  A1 b 100 52 (N/A) 47 (N/A) 12 (N/A) 95 (N/A) 97 (N/A) 
  A2.1 -- 100 95 (0.9) 61 (0.2) 50 (-0.03) 52 (0.002) 
  A2.2 -- -- 100 65 (0.3) 48 (0.02) 50 (0.05) 
  A3 -- -- -- 100 17 (0.01) 15 (0.009) 
  A4 -- -- -- -- 100 98 (0.8) 
  A5 -- -- -- -- -- 100 
Abbreviations: VCA: Epstein-Barr virus capsid antigen. 
a. Cells with duplicated information are presented as “--”. 
b. All samples were defined as positive by Assay A1. No Kappa value can be estimated, and results are 
presented as “N/A”. 
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Table 3. Percentage agreement (Kappa) for assays measuring IgA antibodies against EBNA1 in 
serum. 
a
 
Assay A8 A9.1 A9.2 A10 A11 A12 
  A8 100 67 (0.7) 76 (0.9) 73 (0.8) 62 (0.2) 68 (0.7) 
  A9.1 -- 100 88 (0.8) 94 (0.8) 29 (0.1) 92 (0.9) 
  A9.2 -- -- 100 94 (0.9) 41 (0.2) 89 (0.7) 
  A10 -- -- -- 100 35 (0.2) 95 (0.7) 
  A11 -- -- -- -- 100 30 (0.1) 
  A12 -- -- -- -- -- 100 
Abbreviations: EBNA1: Epstein-Barr virus nuclear antigen 1. 
a. Cells with duplicated information are presented as “--”. 
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